Search results for "equipos"

showing 10 items of 43 documents

Presenting signs and patient co-variables in Gaucher disease: outcome of the Gaucher Earlier Diagnosis Consensus (GED-C) Delphi initiative.

2019

Background: Gaucher disease (GD) presents with a range of signs and symptoms. Physicians can fail to recognise the early stages of GD owing to a lack of disease awareness, which can lead to significant diagnostic delays and sometimes irreversible but avoidable morbidities. Aim: The Gaucher Earlier Diagnosis Consensus (GED-C) initiative aimed to identify signs and co-variables considered most indicative of early type 1 and type 3 GD, to help non-specialists identify ‘at-risk’ patients who may benefit from diagnostic testing. Methods: An anonymous, three-round Delphi consensus process was deployed among a global panel of 22 specialists in GD (median experience 17.5 years, collectively managin…

Delphi TechniqueDisease outcomethrombocytopeniaMedicina Clínica030204 cardiovascular system & hematology0302 clinical medicine//purl.org/becyt/ford/3.2 [https]Lysosomal storage disease030212 general & internal medicinecomputer.programming_languageGaucher Malaltia de:Ciencias de la información::análisis de sistemas::técnica Delfos [CIENCIA DE LA INFORMACIÓN]lysosomal storage diseaseINBORN ERROR:Information Science::Systems Analysis::Delphi Technique [INFORMATION SCIENCE]Original Article//purl.org/becyt/ford/3 [https]Corrigendum:Diagnosis::Early Diagnosis [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT]medicine.medical_specialtyCIENCIAS MÉDICAS Y DE LA SALUDSPLENOMEGALYConsensusPrognosiLYSOSOMAL STORAGE DISEASEMETABOLISMinborn error03 medical and health sciencesPhysiciansInternal MedicinemedicineHumansHematologíaALGORITHM:enfermedades del sistema nervioso::enfermedades del sistema nervioso central::enfermedades cerebrales::enfermedades cerebrales metabólicas::enfermedades cerebrales metabólicas congénitas::enfermedades por almacenamiento lisosómico del sistema nervioso::esfingolipidosis::enfermedad de Gaucher [ENFERMEDADES]splenomegalyalgorithmGaucher Diseasebusiness.industryTHROMBOCYTOPENIA:Nervous System Diseases::Central Nervous System Diseases::Brain Diseases::Brain Diseases Metabolic::Brain Diseases Metabolic Inborn::Lysosomal Storage Diseases Nervous System::Sphingolipidoses::Gaucher Disease [DISEASES]Original Articlesmedicine.disease:diagnóstico::diagnóstico precoz [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]Early DiagnosisFamily medicinebusinessmetabolismcomputerDelphiInternal medicine journal
researchProduct

Validez estructural de un cuestionario para medir comportamientos eficaces en los equipos de trabajo

2015

Se presenta un estudio de la validez estructural del cuestionario planteado por Philip R. Harris (1995; traducción al castellano realizada por el Centro de Estudios Ramón Areces, 2001) orientado a evaluar la eficacia del comportamiento individual de las personas que trabajan en un equipo. El instrumento se aplicó a una muestra compuesta por 771 empleados pertenecientes a distintos equipos de trabajo existentes en diversas organizaciones dedicadas a la atención a la dependencia. La realización del análisis factorial exploratorio reveló una estructura factorial de tres dimensiones, etiquetadas como 'habilidades comunicativas', 'expresión emocional' y 'aceptación', que explicaba el 63.2% de la…

Habilidades para el trabajo en equipoPsicologia socialemocionesApplied psychologylcsh:BF1-990EmocionsStructural validitycomunicaciónaceptaciónFactor structureExploratory factor analysisTest (assessment)159.9 - Psicologíaconducta y equipos de trabajolcsh:PsychologyComunicació Aspectes socialsEffective teamEmotional expressionCommunication skillsanálisis factorialPsychologyGeneral PsychologyAnales de Psicología
researchProduct

Assessing the impact of COVID-19 on liver cancer management (CERO-19)

2021

[Background & Aims] The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems and it may have heavily impacted patients with liver cancer (LC). Herein, we evaluated whether the schedule of LC screening or procedures has been interrupted or delayed because of the COVID-19 pandemic.

Hepatocellular carcinomaLCmedicine.medical_treatment:diagnóstico::toma de decisiones clínicas [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]NursesRC799-869Liver transplantationCholangiocarcinomaClinical trialsENS-CCAInterquartile rangeDecisió Presa dePandemic:Other subheadings::/diagnosis [Other subheadings]:virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES]CERO-19Pandèmia de COVID-19 2020-Immunology and AllergyiCCA intrahepatic cholangiocarcinomaCOVID-19 coronavirus disease 2019Liver Cancer Outcome in the COVID-19-pandemic ProjectSettore MED/12 - Gastroenterologiaddc:617IQRGastroenterologyBCLC Barcelona Clinic Liver Cancer:Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES]:neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias hepáticas [ENFERMEDADES]Diseases of the digestive system. GastroenterologyManagementClinical PracticeClinical trialEuropean Network for the Study of Cholangiocarcinoma:Diagnosis::Clinical Decision-Making [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT]Fetge - Malalties - DiagnòsticInterquartile rangeLiver cancerLiver cancerPROGRESSION-FREE SURVIVALLiver Cancermedicine.medical_specialtyCoronavirus disease 2019 (COVID-19):Otros calificadores::/diagnóstico [Otros calificadores]610 Medicine & health:Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Liver Neoplasms [DISEASES]LT liver transplantationArticleBarcelona Clinic Liver CancerInternal MedicinemedicineENS-CCA European Network for the Study of CholangiocarcinomaHepatologybusiness.industryCERO-19 Liver Cancer Outcome in the COVID-19-pandemic ProjectCOVID-19IQR Interquartile rangemedicine.diseaseBCLCClinical trialEmergency medicineObservational study610 Medizin und GesundheitbusinessHCC hepatocellular carcinomaLC liver cancerSARS-CoV-2 severe acute respiratory syndrome coronavirus-2
researchProduct

Epidemiology of intra-abdominal infection and sepsis in critically ill patients: "AbSeS", a multinational observational cohort study and ESICM Trials…

2019

Pardo-Oviedo, Juan Mauricio/0000-0003-0084-3449; Lopez-Delgado, Juan Carlos/0000-0003-3324-1129; Corradi, Francesco/0000-0002-5588-2608; De Backer, Daniel/0000-0001-9841-5762; POTA, VINCENZO/0000-0001-9999-3388; Tomescu, Dana/0000-0001-9673-5754; Sabetian, Golnar/0000-0001-8764-2150; Girardis, Massimo/0000-0002-2453-0829; Brazzi, Luca/0000-0001-7059-0622; Leone, Marc/0000-0002-3097-758X; Zabolotskikh, Igor Borisovich/0000-0002-3623-2546; De Lange, Dylan/0000-0002-0191-7270; ALMEKHLAFI, GHALEB A./0000-0002-0323-7025; Elke, Gunnar/0000-0002-4948-1605; Grigoras, Ioana/0000-0001-9412-9574; Czuczwar, Miroslaw/0000-0002-9025-6717; Nora, David/0000-0002-1133-7368; Masjedi, Mansoor/0000-0001-6175-9…

Infection riskMaleBIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences.Antibiotic resistanceTracte gastrointestinal - MalaltiesDefinitionsCritical Care and Intensive Care MedicineTHERAPYDEFINITIONS:Infections::Intraabdominal Infections [DISEASES]0302 clinical medicineIntensive care; Intra-abdominal infection; Mortality; Multidrug resistance; Peritonitis; Sepsis;[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesObservational studySeptic shockIntensive care; Intra-abdominal infection; Mortality; Multidrug resistance; Peritonitis; SepsisComputingMilieux_MISCELLANEOUSCritical Illness/epidemiology[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseasesBIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti.Intraabdominal Infections/epidemiologyAbdominal infectionMulticenter study3. Good healthManagementClinical trialCohort[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/VirologyCohort analysisCommunity acquired infectionCohort studyHumanmedicine.medical_specialtyCarbapenem resistanceCritical IllnessPeritoneal dialysisPeritonitisVancomycin resistant enterococcusMajor clinical studyPeritonitisArticle03 medical and health sciencesAntibiotic resistance[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemIntensive careSepsisSettore MED/41 - ANESTESIOLOGIAHumansCritical care medicineHospital infectionAgedScience & TechnologyLiver failureAntibiotic therapymedicine.disease[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/BacteriologyEpidemiologic Studies030228 respiratory systemIntensive Care Unit; Sepsis (Diptera); Septic ShockRisk factorHuman medicineGeneral & internal medicineCongestive heart failureOriginalMultidrug resistanceCohort StudiesRisk FactorsCause of DeathEpidemiologyPrevalenceMedicine and Health SciencesAbdominal abscessSepsis/epidemiologyMiddle agedAntifungal therapy2. Zero hungerPeritonitiAntibiotic agentBiliary tract infectionIntensive care ; Intra-abdominal infection ; Mortality ; Multidrug resistance ; Peritonitis ; SepsisMiddle Aged:infecciones bacterianas y micosis::infección::infecciones intraabdominales [ENFERMEDADES]PREVALENCE:Infections::Sepsis [DISEASES]:técnicas de investigación::métodos epidemiológicos::características de los estudios epidemiológicos::estudios epidemiológicos::estudios de cohortes [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]Methicillin resistant staphylococcus aureusRaonament basat en casosFemaleCritically ill patientLife Sciences & BiomedicineAntifungal agentAdult:Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics::Epidemiologic Studies::Cohort Studies [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT]Predictive value:infecciones bacterianas y micosis::infección::sepsis [ENFERMEDADES]NOSepsisIntra-abdominal infectionCritical Care MedicineInternal medicineGeneral & Internal MedicinemedicineMANAGEMENTJournal Article[SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/ParasitologySepticèmiaMortalitybusiness.industrySeptic shockPancreas diseaseMalnutrition030208 emergency & critical care medicineTyphlitisToxic megacolonIntensive careIntraabdominal InfectionsTherapyLate onset disorderbusiness
researchProduct

Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases

2022

Population screening; Liver fibrosis; Early diagnosis Cribratge de població; Fibrosi hepàtica; Diagnòstic precoç Cribado de población; Fibrosis hepática; Diagnóstico precoz Cirrhosis, highly prevalent worldwide, develops after years of hepatic inflammation triggering progressive fibrosis. Currently, the main etiologies of cirrhosis are non-alcoholic fatty liver disease and alcohol-related liver disease, although chronic hepatitis B and C infections are still major etiological factors in some areas of the world. Recent studies have shown that liver fibrosis can be assessed with relatively high accuracy noninvasively by serological tests, transient elastography, and radiological methods. Thes…

Liver Cirrhosismedicine.medical_specialtyCirrosi hepàtica - DiagnòsticCirrhosisFibrosiBiopsy:enfermedades del sistema digestivo::enfermedades hepáticas::cirrosis hepática [ENFERMEDADES]Population:Digestive System Diseases::Liver Diseases::Liver Cirrhosis [DISEASES]:Otros calificadores::/diagnóstico [Otros calificadores]DiseaseFetge -- Malalties:Diagnosis::Diagnostic Techniques and Procedures::Mass Screening [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT]AsymptomaticGastroenterologyGlobal Burden of DiseaseLiver diseaseHepatitis B ChronicSDG 3 - Good Health and Well-beingLiver Function TestsNon-alcoholic Fatty Liver DiseaseRisk FactorsFibrosisInternal medicinePrevalenceCribatge (Medicina):Other subheadings::/diagnosis [Other subheadings]:diagnóstico::técnicas y procedimientos diagnósticos::cribado sistemático [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]HumansMass ScreeningMedicineeducationliver fibrosiseducation.field_of_studyHepatologybusiness.industryFatty liverCirrosiHepatitis C Chronicmedicine.diseaseEarly DiagnosisLiverDisease ProgressionElasticity Imaging Techniquesmedicine.symptomTransient elastographybusinessHepatology
researchProduct

Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumors

2020

Inhibidor d'AKT; Càncer avançat; Fase I Inhibidor de AKT; Cáncer avanzado; Fase I AKT inhibitor; Advanced cancer; Phase I Background This phase Ib study evaluated the safety, tolerability, pharmacokinetics, and preliminary efficacy of the oral AKT inhibitor ipatasertib and chemotherapy or hormonal therapy in patients with advanced or metastatic solid tumors to determine combined dose-limiting toxicities (DLTs), maximum tolerated dose, and recommended phase II doses and schedules. Patients and methods The clinical study comprised four combination treatment arms: arm A (with docetaxel), arm B [with mFOLFOX6 (modified leucovorin, 5-fluorouracil, and oxaliplatin)], arm C (with paclitaxel), and …

Male0301 basic medicinemedicine.medical_specialtyMaximum Tolerated Dosemedicine.medical_treatmentCàncer - Quimioteràpia:Otros calificadores::Otros calificadores::/efectos adversos [Otros calificadores]GastroenterologyAKT inhibitorPiperazinesMedicaments antineoplàstics - Efectes secundaris:neoplasias [ENFERMEDADES]03 medical and health scienceschemistry.chemical_compound0302 clinical medicineNeoplasmsInternal medicineAntineoplastic Combined Chemotherapy Protocols:Other subheadings::Other subheadings::/adverse effects [Other subheadings]medicineadvanced cancerHumansEnzalutamide:terapéutica::protocolos clínicos::protocolos antineoplásicos::protocolos de quimioterapia antineoplásica combinada [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]Adverse effectChemotherapybusiness.industryHematologyphase I:Therapeutics::Clinical Protocols::Antineoplastic Protocols::Antineoplastic Combined Chemotherapy Protocols [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT]Oxaliplatin:Neoplasms [DISEASES]Pyrimidines030104 developmental biologyOncologyDocetaxelTolerabilityPaclitaxelchemistryResponse Evaluation Criteria in Solid Tumors030220 oncology & carcinogenesisbusinessmedicine.drugAnnals of Oncology
researchProduct

Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor

2017

Prevenció; Atac d'angioedema; Inhibidor C1 Prevención; Ataque de angioedema; Inhibidor C1 Prevention; Angioedema attack; C1 inhibitor BACKGROUND: Hereditary angioedema is a disabling, potentially fatal condition caused by deficiency (type I) or dysfunction (type II) of the C1 inhibitor protein. In a phase 2 trial, the use of CSL830, a nanofiltered C1 inhibitor preparation that is suitable for subcutaneous injection, resulted in functional levels of C1 inhibitor activity that would be expected to provide effective prophylaxis of attacks. METHODS: We conducted an international, prospective, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase 3 trial to evaluate the …

Male:aminoácidos péptidos y proteínas::péptidos::serpinas::proteínas inactivadoras del complemento C1::proteína inhibidora del complemento C1 [COMPUESTOS QUÍMICOS Y DROGAS]0301 basic medicine:Otros calificadores::Otros calificadores::/prevención & control [Otros calificadores]Enzims proteolítics - InhibidorsSelf AdministrationSeverity of Illness Indexlaw.inventionC1-inhibitorSubcutaneous injection0302 clinical medicineRandomized controlled triallawCross-Over StudiesHereditary Angioedema Types I and IIbiologyEdema - PrevencióGeneral Medicine:Cardiovascular Diseases::Vascular Diseases::Angioedema::Angioedemas Hereditary [DISEASES]AnesthesiaHereditary angioedema:Other subheadings::Other subheadings::/administration & dosage [Other subheadings]Female:Amino Acids Peptides and Proteins::Peptides::Serpins::Complement C1 Inactivator Proteins::Complement C1 Inhibitor Protein [CHEMICALS AND DRUGS]medicine.symptomComplement C1 Inhibitor Protein:enfermedades cardiovasculares::enfermedades vasculares::angioedema::angioedemas hereditarios [ENFERMEDADES]AdultRiskmedicine.medical_specialtyInjections Subcutaneous:Aminoácidos Péptidos y Proteínas::Péptidos::Serpinas::Proteínas Inactivadoras del Complemento 1::Proteína Inhibidora del Complemento C1 [COMPUESTOS QUÍMICOS Y DROGAS]Placebo:Other subheadings::Other subheadings::/prevention & control [Other subheadings]03 medical and health sciencesDouble-Blind MethodInternal medicinemedicineHumans:Therapeutics::Drug Therapy::Drug Administration Routes::Injections::Injections Subcutaneous [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT]:Otros calificadores::Otros calificadores::/administración & dosificación [Otros calificadores]Dose-Response Relationship DrugAngioedemabusiness.industry:Terapéutica::Tratamiento Farmacológico::Vías de Administración de Medicamentos::Inyecciones::Inyecciones Subcutáneas [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]Injeccions hipodèrmiquesmedicine.diseaseCrossover studyClinical trial:terapéutica::farmacoterapia::vías de administración de medicamentos::inyecciones::inyecciones subcutáneas [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]030104 developmental biology030228 respiratory systembiology.proteinbusinessNew England Journal of Medicine
researchProduct

“Near-TME”: proposed standardisation of the technique for proctectomy in male patients with ulcerative colitis

2022

Abstract Background The aim of the present study was to describe in detail an approach to proctectomy in ulcerative colitis (UC), which can be standardized; near-total mesorectal excision (near-TME), to prevent injuries to autonomic pelvic nerves and subsequent sexual dysfunction. Methods We demonstrate the technique ex vivo on a cadaver from a male patient in lithotomy position and on a sagittal section of a male pelvis. We also demonstrate the technique in vivo in two male patients diagnosed with UC, with no history of sexual dysfunction or bowel neoplasia. The study was performed at the Human Embryology and Anatomy Department. University of Valencia, Spain. Results The posterolateral dis…

MaleClose rectal dissection:Surgical Procedures Operative::Digestive System Surgical Procedures::Proctectomy [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT]Pelvi:Digestive System Diseases::Gastrointestinal Diseases::Gastroenteritis::Colitis::Colitis Ulcerative [DISEASES]Inflammatory bowel diseasesInflammatory bowel diseasePelvis:enfermedades del sistema digestivo::enfermedades gastrointestinales::gastroenteritis::colitis::colitis ulcerosa [ENFERMEDADES]Colitis ulcerosa - CirurgiaHumansAutonomic PathwaysUlcerative coliti:intervenciones quirúrgicas::procedimientos quirúrgicos del sistema digestivo::proctectomía [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]ProctectomyRectal NeoplasmsRectumGastroenterology:Otros calificadores::Otros calificadores::/cirugía [Otros calificadores]Surgical anatomyExtirpació (Cirurgia)Intra-mesorectal:Other subheadings::Other subheadings::/surgery [Other subheadings]Ulcerative colitisAutonomic PathwayColitis UlcerativeSurgerysense organsHumanTechniques in Coloproctology
researchProduct

The oral KIF11 inhibitor 4SC‐205 exhibits antitumor activity and potentiates standard and targeted therapies in primary and metastatic neuroblastoma …

2021

Inhibidor de KIF11; Terapias dirigidas; Metástasis Inhibidor de KIF11; Teràpies dirigides; Metàstasi KIF11 inhibitor; Targeted therapies; Metastasis In summary, our study provides a rationale for the future therapeutic integration in clinical trials of 4SC-205, an structurally distinct oral KIF11 inhibitor that shows potent antitumor activity in multiple preclinical neuroblastoma models and sensitizes neuroblastoma cells to standard chemotherapy and specific neuroblastoma-targeted therapies. The financial support for this research was provided by Instituto de Salud Calos III (PI20/00530 to Miguel F. Segura; PI20/01107 to Rosa Noguera; PI17/02248 and CPII18/00027 to Anna Santamaria; PI19/013…

Medicine (General)Neuroblastoma - Tractament:neoplasias::neoplasias por tipo histológico::neoplasias de células germinales y embrionarias::tumores neuroectodérmicos::neoplasias neuroepiteliales::tumores neuroectodérmicos primitivos::tumores neuroectodérmicos primitivos periféricos::neuroblastoma [ENFERMEDADES]Metastatic neuroblastomaMedicació oralMedicaments antineoplàstics - Ús terapèutic:Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores]Medicine (miscellaneous)Administration OralKinesinsAntineoplastic Agents:Other subheadings::Other subheadings::/drug therapy [Other subheadings]Letter to Editor:Neoplasms::Neoplasms by Histologic Type::Neoplasms Germ Cell and Embryonal::Neuroectodermal Tumors::Neoplasms Neuroepithelial::Neuroectodermal Tumors Primitive::Neuroectodermal Tumors Primitive Peripheral::Neuroblastoma [DISEASES]MiceNeuroblastomaR5-920Cell Line Tumor:terapéutica::farmacoterapia::vías de administración de medicamentos::administración oral [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]MedicineAnimalsHumansAntitumor activityPrimary (chemistry)business.industry:acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos [COMPUESTOS QUÍMICOS Y DROGAS]Disease Models Animal:Therapeutics::Drug Therapy::Drug Administration Routes::Administration Oral [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT]Cancer researchMolecular Medicine:Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents [CHEMICALS AND DRUGS]businessClinical and Translational Medicine
researchProduct

The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Tri…

2021

This article belongs to the Collection The Biomarkers for the Diagnosis and Prognosis in Cancer.

Neuroblastoma RAS viral oncogene homologOncologyCancer Researchgenetic riskMyeloid neoplasialeukemic cells0302 clinical medicinecytarabineclinical trials and observations:Other subheadings::/diagnosis [Other subheadings]MedicineComplete remissionazacytidineolder adultsRC254-282variantsLeukemiaAzacytidineHazard ratioleukemiaVariantsCytarabineacute:Neoplasms::Neoplasms by Histologic Type::Leukemia::Leukemia Myeloid::Leukemia Myeloid Acute [DISEASES]Neoplasms. Tumors. Oncology. Including cancer and carcinogensMyeloid leukemiaFludarabineLeukemiaOncology030220 oncology & carcinogenesisNGSOlder adultsLeucèmia mieloide aguda - Tractamentmyeloid neoplasiaMyelocyticmedicine.drugmedicine.medical_specialtymyelocyticcomplete remission:Otros calificadores::/diagnóstico [Otros calificadores]Subgroup analysisLeukemic cellsAcutePrognostic factorsArticle:neoplasias::neoplasias por tipo histológico::leucemia::leucemia mieloide::leucemia mieloide aguda [ENFERMEDADES]03 medical and health sciencesInternal medicineGenetic riskbusiness.industryprognostic factors:diagnóstico::pronóstico::resultado del tratamiento [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]Odds ratio:Diagnosis::Prognosis::Treatment Outcome [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT]medicine.diseaseAvaluació de resultats (Assistència sanitària)CytarabinebusinessClinical trials and observations030215 immunology
researchProduct